Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature

Eur J Haematol. 2015 Jun;94(6):554-7. doi: 10.1111/ejh.12396. Epub 2014 Jul 2.

Abstract

Brentuximab Vedotin is an antibody - drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab Vedotin in a 64-yr-old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.

Keywords: Brentuximab Vedotin; CD30; anaplastic large cell lymphoma; cytokine release syndrome; infusion reaction.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brentuximab Vedotin
  • Cyclophosphamide / therapeutic use
  • Cytokines / metabolism*
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Humans
  • Immunoconjugates / administration & dosage*
  • Immunoconjugates / adverse effects*
  • Lymphoma, Large-Cell, Anaplastic / complications*
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Lymphoma, Large-Cell, Anaplastic / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prednisolone / therapeutic use
  • Remission Induction
  • Syndrome
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Antineoplastic Agents
  • Cytokines
  • Immunoconjugates
  • Vincristine
  • Etoposide
  • Brentuximab Vedotin
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone

Supplementary concepts

  • CHOEP protocol